MX2022012536A - Composiciones que comprenden polisacaridos sulfatados. - Google Patents

Composiciones que comprenden polisacaridos sulfatados.

Info

Publication number
MX2022012536A
MX2022012536A MX2022012536A MX2022012536A MX2022012536A MX 2022012536 A MX2022012536 A MX 2022012536A MX 2022012536 A MX2022012536 A MX 2022012536A MX 2022012536 A MX2022012536 A MX 2022012536A MX 2022012536 A MX2022012536 A MX 2022012536A
Authority
MX
Mexico
Prior art keywords
sulfated polysaccharides
inflammatory
compositions
synergistic
composition
Prior art date
Application number
MX2022012536A
Other languages
English (en)
Inventor
Doron Friedman
Original Assignee
Seanergy Dermatology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Seanergy Dermatology Ltd filed Critical Seanergy Dermatology Ltd
Publication of MX2022012536A publication Critical patent/MX2022012536A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/02—Algae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

La presente invención se relaciona con una composición antiinflamatoria sinérgica que comprende uno o más agentes antiinflamatorios como un fármaco antiinflamatorio esteroideo, no esteroideo (NSAID) o un cannabinoide en combinación con uno o más polisacáridos sulfatados. La invención está dirigida además a un método de tratamiento de la inflamación y enfermedades inflamatorias usando la composición sinérgica.
MX2022012536A 2016-12-11 2019-06-10 Composiciones que comprenden polisacaridos sulfatados. MX2022012536A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662432628P 2016-12-11 2016-12-11

Publications (1)

Publication Number Publication Date
MX2022012536A true MX2022012536A (es) 2022-11-07

Family

ID=60788649

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2019006769A MX2019006769A (es) 2016-12-11 2017-12-10 Composiciones que comprenden polisacaridos sulfatados.
MX2022012536A MX2022012536A (es) 2016-12-11 2019-06-10 Composiciones que comprenden polisacaridos sulfatados.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2019006769A MX2019006769A (es) 2016-12-11 2017-12-10 Composiciones que comprenden polisacaridos sulfatados.

Country Status (13)

Country Link
US (3) US11617762B2 (es)
EP (1) EP3551175A1 (es)
JP (2) JP7253494B2 (es)
KR (1) KR20190095937A (es)
CN (1) CN110248651A (es)
AU (1) AU2017372976B2 (es)
BR (1) BR112019011406A2 (es)
CA (1) CA3046764A1 (es)
IL (1) IL267095A (es)
MX (2) MX2019006769A (es)
PH (1) PH12019501323A1 (es)
RU (1) RU2019121559A (es)
WO (1) WO2018104950A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11617762B2 (en) 2016-12-11 2023-04-04 Seanergy Dermatology Ltd. Compositions comprising sulfated polysaccharides
US11766421B2 (en) 2017-09-25 2023-09-26 Surface Ophthalmics, Inc. Ophthalmic pharmaceutical compositions and methods for treating ocular surface disease
EP3810125A4 (en) * 2018-06-03 2022-02-23 Glycomira Therapeutics, Inc. PROCEDURES TO PREVENT SERIOUS HEALTH EFFECTS AND/OR TISSUE DAMAGE FOLLOWING EXPOSURE TO IONIZING RADIATION AND/OR CHEMOTHERAPY
EP3902525A4 (en) * 2018-12-27 2022-09-28 Surface Ophthalmics, Inc. OPHTHALMIC PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THE TREATMENT OF OCULAR SURFACE DISEASES
CN113795246A (zh) * 2019-05-06 2021-12-14 福多兹制药公司 用于治疗关节疼痛和炎症的可注射缓释制剂
JP2021080187A (ja) * 2019-11-15 2021-05-27 株式会社明治 ウイルス増殖を抑制するための組成物
US11464827B2 (en) * 2020-03-10 2022-10-11 Anewsha Holding Group Llc Antiviral pharmaceutical compositions and method of manufacturing
GB202011973D0 (en) * 2020-07-31 2020-09-16 Microa As Uses of saccharides from prasinococcales
KR102308155B1 (ko) * 2021-04-23 2021-10-05 주식회사 바스케어 천연 식물을 활용한 복합 기능성 피부 개선용 화장료 조성물 및 이의 제조방법
CN115486505B (zh) * 2022-09-21 2023-05-30 营口理工学院 具有辅助降血糖功效的海洋藻类多糖保健饮料及制备方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LU77562A1 (de) 1977-06-17 1979-03-26 Ciba Geigy Ag Verfahren zur herstellung von neuen pharmazeutischen praeparaten
GB8530796D0 (en) * 1985-12-13 1986-01-22 Beecham Group Plc Pharmaceutical composition
JP2544136B2 (ja) * 1986-05-23 1996-10-16 第一製薬株式会社 硫酸化多糖体ｄｓ４１５２を含有する血管新生抑制剤及び抗腫瘍剤
US5541166A (en) 1987-01-23 1996-07-30 The Australian National University Sulphated polysaccharides having anti-metastatic and/or anti-inflammatory activity
US5668116A (en) 1987-03-19 1997-09-16 Anthropharm Pty. Limited Anti-inflammatory compounds and compositions
EP0632726A4 (en) * 1991-12-20 1995-11-29 Us Army METHOD FOR TREATING KAPOSI'S DISEASE AND BLOCKING OR INHIBITING VASCULAR PERMEABILITY.
JP4098394B2 (ja) * 1998-03-17 2008-06-11 株式会社ヤクルト本社 非ステロイド性消炎・鎮痛剤の副作用低減剤
AU2005205422B2 (en) * 2004-01-20 2008-04-24 Panacea Biotec Ltd. Compostions comprising glycosaminoglycan and nonsteroidal anti-inflammatory drug
WO2006003521A1 (en) 2004-02-06 2006-01-12 Monash University High dose, short interval use of sulfated polysaccharides for the treatment of infections
JP4601595B2 (ja) * 2006-09-28 2010-12-22 小林製薬株式会社 消炎鎮痛用経口医薬組成物
JP2012092067A (ja) * 2010-10-28 2012-05-17 Kowa Co 非ステロイド性消炎鎮痛外用剤
US20130273096A1 (en) 2011-10-05 2013-10-17 Bruce A. Daniels Therapeutic Sulfated Polysaccharides, Compositions Thereof, and Methods for Treating Patients
JP2015131770A (ja) * 2014-01-09 2015-07-23 国立大学法人 熊本大学 スイゼンジノリ由来多糖体を用いた胃粘膜障害を軽減する溶液組成物
WO2016056001A1 (en) * 2014-10-06 2016-04-14 Algamed Therapeutics (A.M.T) Ltd Compositions comprising sulfated polysaccharides and uses thereof
US9833461B2 (en) * 2015-10-23 2017-12-05 Ctt Pharma Inc. Therapeutic compositions comprising cannabidiol and corticosteroids
JP2017079615A (ja) * 2015-10-25 2017-05-18 アーサーコーポレーション株式会社 アサ種子油及び褐藻類由来の健康食品
CN105920020B (zh) * 2016-06-23 2019-01-08 潘海英 一种治疗肺部疾病的药物组合物及其制备方法和用途
US11617762B2 (en) 2016-12-11 2023-04-04 Seanergy Dermatology Ltd. Compositions comprising sulfated polysaccharides

Also Published As

Publication number Publication date
PH12019501323A1 (en) 2019-09-16
EP3551175A1 (en) 2019-10-16
KR20190095937A (ko) 2019-08-16
AU2017372976A1 (en) 2019-07-11
CA3046764A1 (en) 2018-06-14
CN110248651A (zh) 2019-09-17
US11166978B2 (en) 2021-11-09
WO2018104950A1 (en) 2018-06-14
US11617762B2 (en) 2023-04-04
JP7253494B2 (ja) 2023-04-06
BR112019011406A2 (pt) 2019-10-15
IL267095A (en) 2019-08-29
JP2020500945A (ja) 2020-01-16
AU2017372976B2 (en) 2023-12-07
US20200171075A1 (en) 2020-06-04
US20230346828A1 (en) 2023-11-02
JP2023040008A (ja) 2023-03-22
MX2019006769A (es) 2019-12-05
RU2019121559A3 (es) 2021-02-24
US20200360422A1 (en) 2020-11-19
RU2019121559A (ru) 2021-01-14

Similar Documents

Publication Publication Date Title
PH12019501323A1 (en) Compositions comprising sulfated polysaccharides
ZA202007007B (en) Mcl-1 inhibitors
CL2021003196A1 (es) Terapias combinadas dirigidas a pd-1, tim-3, y lag-3 (divisional de solicitud n° 201902850)
PH12020500240A1 (en) Anti-cd39 antibodies, compositions comprising anti-cd39 antibodies and methods of using anti-cd39 antibodies
NZ757213A (en) Compositions of plinabulin and use thereof
NZ730865A (en) Peptides having anti-inflammatory properties
CL2020000632A1 (es) Composición y método para el tratamiento del autismo.
CL2015002710A1 (es) Composiciones de arni contra el componente c5 del complemento y métodos para su uso.
MX2017015990A (es) Composiciones topicas que comprenden un corticosteroide y un retinoide para tratar psoriasis.
MX2019015311A (es) Composiciones de ésteres de ácido cannabidiólico y usos de las mismas.
BR112016023815A2 (pt) composições tópicas para o alívio da dor, produção e uso
MX2015016100A (es) Inhibidores de criopirina para prevenir y tratar la inflamacion.
CL2022002247A1 (es) Anticuerpos de cadena pesada que se unen a cd22 (divisional de la solicitud 202001703)
BR112017019352A2 (pt) composições tópicas comprimidas a corticosteróide aplicações relacionadas
AR101236A1 (es) Composiciones para el cuidado oral
CL2018001548A1 (es) Tratamiento de colestasis intrahepática y enfermedades del hígado relacionadas
MX2021007899A (es) Composiciones con inhibidor selectivo de la trans-se?alizacion de il-6.
PE20200338A1 (es) Composiciones cannabinoides novedosas y metodos para tratar la epilepsia infantil
MX2018007871A (es) Composiciones para el cuidado personal.
MX2021000719A (es) Composicion de microbiota fecal, para su uso en la reduccion de la inflamacion inducida por tratamiento.
WO2019043176A3 (en) HISTONE-DEACETYLASE INHIBITOR IN COMBINATION WITH ANTIMETABOLITE AGENT FOR CANCER THERAPY
MX2022015456A (es) Composiciones de maca y metodos de uso.
PE20180691A1 (es) Variantes de il-37
EA201791937A1 (ru) Противовоспалительные полипептиды
NZ713440A (en) Nsaid administration and related compositions, methods and systems.